

10 June 2024

To: Recipients of CLSI M53, 2nd ed.  
From: Jennifer K. Adams, MLS(ASCP), MSHA  
Vice President, Standards and Quality  
Subject: Corrections

This notice is intended to inform users of corrections made to CLSI M53, *Criteria for Laboratory Testing and Diagnosis of Human Immunodeficiency Virus Infection*, 2nd ed. The corrections are described below and shown as highlighted and/or stricken text in the excerpts.

#### **Subchapter 4.1.4. Limitations:**

In the second paragraph regarding initial and supplemental tests, the sentence preceding the bullet lead-in text is listed incorrectly as, “Using these tests in combination results in a high clinical sensitivity (> 99%).” The sentence has been corrected to read, “Using these tests in combination results in a high clinical ~~sensitivity~~ **specificity** (> 99%).”

#### **Subchapter 6.1.2. Nucleic Acid Detection:**

In the first paragraph regarding viral RNA levels, the second sentence is listed incorrectly as, “Viral RNA levels are typically highest (> 10<sup>6</sup> copies/mL) during AHI than at any other time in the natural course of the infection.” The sentence has been corrected to read, “Viral RNA levels are typically highest (> ~~10<sup>6</sup>~~ **10<sup>6</sup>** copies/mL) during AHI than at any other time in the natural course of the infection.”

If you require any additional clarification regarding these corrections, please contact CLSI Customer Service ([customerservice@clsi.org](mailto:customerservice@clsi.org)).